The incidence of melanoma, the most serious
|
|
- Ami Campbell
- 5 years ago
- Views:
Transcription
1 Efectiveness nd sfety of ipilimumb therpy in dvnced melnom: evidence from clinicl prctice sites in the US Kim A Mrgolin, MD, Ahmd Trhini, MD, PhD, b Sumti Ro, PhD, c Monic Ktyl, JD, MPH, d I-Fen Chng, PhrmD, c Dougls B Johnson, MD, e Sekwon Jng, MD, f Joseph I Clrk, MD, g nd Dvid McDermott, MD h University of Wshington, Settle, Wshington; b University of Pittsburgh, Pittsburgh, Pennsylvni; c Bristol-Myers Squibb, Plinsboro, New Jersey; d Medicl Dt Anlytics, Prsippny, New Jersey; e Vnderbilt University Medicl Center, Nshville, Tennessee; f Wshington Cncer Institute t MedStr Wshington Hospitl Center, Wshington, DC; g Loyol University Medicl Center, Crdinl Bernrdin Cncer Center, Mywood, Illinois; nd h Beth Isrel Deconess Medicl Center, Boston, Msschusetts Bckground Ipilimumb ws pproved in 2011 by the US Food nd Drug Administrtion in 2011 for the tretment of unresectble or metsttic (dvnced) melnom, lthough pivotl dt using the pproved 3 mg/kg monotherpy q3w 4 were vilble only for ptients with previously treted disese. Objective To investigte ptient nd disese chrcteristics, survivl outcomes, nd sfety in tretment-nïve ptients receiving ipilimumb therpy. Methods Adult ptients with tretment-nïve dvnced melnom who received 1 dose of ipilimumb 3 mg/kg during April 2011-Sept 2012, with 12 months hving elpsed since the strt of tretment, were identifed from 34 US sites. Personnel from ech study site retrospectively bstrcted existing dt from individul ptient medicl records, which were collected nd vlidted by n independent reserch orgniztion. Results In ll, 273 ptients were included in the study. The medin ge of the totl study popultion ws 64 yers (rnge, 26-91), nd 64.8% were men. At dignosis, 56.0% were stge IV M1c, nd 12.1% hd brin metstses. 50 ptients hd BRAF muttion, 181 were BRAF wild-type, nd BRAF sttus ws not known for % of ptients received ll 4 plnned doses of ipilimumb. Medin survivl from initition of ipilimumb tretment ws 14.5 months (95% confdence index [CI], ). The overll one-yer survivl rte ws 59.2% (95% CI, ); nd 71.0% nd 54.9% for ptients with BRAF-mutted nd wild-type tumors, respectively. Adverse events of ny grde, grde 3, nd grde 4 occurred in 164 ptients (60.1%), 45 (16.5%), nd 8 (2.9%), respectively. The most common grde 3 or 4 dverse events were colitis (4.0%), ftigue (2.9%), nd dirrhe (1.5%). Drugrelted dverse events were primrily immune-relted nd occurred in 147 ptients (53.8%), including grde 3/4 in 15.7% of ptients (13.9% nd 1.8%, respectively). No deths were ttributed to ipilimumb. Conclusions This observtionl study provides rel-world, clinicl prctice evidence supporting improved survivl with the pproved ipilimumb 3 mg/kg monotherpy in ptients with tretment-nïve dvnced melnom, including prolonged survivl in some ptients. The sfety profle ws consistent with tht reported in clinicl trils. Funding/sponsorship Bristol-Myers Squibb. Dr Johnson is supported by NIH trining grnt K12 CA The incidence of melnom, the most serious form of skin cncer, is rising globlly. 1,2 Although most ptients re dignosed nd treted t n erly stge of the disese nd hve good prognosis, survivl mong ptients with unresectble or metsttic (dvnced) melnom remins poor. In the United Sttes, n estimted 9,940 deths from melnom will occur in 2015; 1 in Europe, melnom ccounts for n estimted 20,000 deths nnully. 2 Ptients with dvnced melnom historiclly hd disml prognosis, with medin survivl of less thn yer. 3,4 In met-nlysis of 2,100 ptients with dvnced melnom from 42 phse 2 coopertive group clinicl trils with ccrul closing between 1975 nd 2005, the medin overll survivl (OS) ws 6.2 months (95% confdence intervl [CI], ), with 25.5% (95% CI, ) live t 1 yer. 3 Another recent systemtic review estimted medin OS for stge IV melnom of bout 8 months, Accepted for publiction Mrch 13, Correspondence: Sumti Ro, PhD; sumti.ro@bms.com. Disclosures: Drs Ro nd Chng re employees of Bristol-Myers Squibb. Dr Clrk receives grnts nd spekers bureu fees from Bristol-Myers Squibb. Dr McDermott reports compenstion from Bristol-Myers Squibb for dvisory bord ttendnce. Dr Trhini reports grnts received nd compenstion from Bristol-Myers Squibb for dvisory bord ttendnce. Dr Mrgolin nd Ms Ktyl receive grnts from Bristol-Myers Squibb. Dr Jng nd Dr Johnson report nothing to disclose. JCSO 2015;13: Frontline Medicl Communictions. DOI /jcso Volume 13/Number 4 April 2015 g THE JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY 131
2 with bout 10% of ptients surviving more thn 5 yers. 4 Beginning in 2010, however, phse 3 studies of severl novel gents showed sttisticlly improved OS in ptients with dvnced melnom. 5-7 Tese fndings further vlidted the use of immunotherpy nd introduced moleculrly trgeted therpy for the tretment of dvnced melnom, resulting in the vilbility of severl new gents for use in routine clinicl prctice. 8 Te frst of these new gents ws the frst-in-clss immune checkpoint inhibitor ipilimumb, humn monoclonl ntibody. Ipilimumb trgets the cytotoxic T-lymphocyte ssocited ntigen 4 (CTLA-4) receptor, blocking its inhibitory mechnisms nd thereby ugmenting T-lymphocyte medited ntitumor immune responses. Ipilimumb monotherpy, 3 mg/kg every 3 weeks for 4 doses, ws pproved in 2011 by the US Food nd Drug Administrtion on the bsis of signifcnt improvements in OS demonstrted in 2 pivotl, phse 3 rndomized, double-blind trils in ptients with dvnced melnom. Te frst study ws conducted in previously treted ptients; ipilimumb 3 mg/kg prolonged OS, whether dministered s monotherpy (medin, 10.1 months) or combined with glycoprotein 100 (gp100) peptide vccine (medin, 10.0 months), over gp100 lone (medin, 6.4 months; hzrd rtio [HR] for deth for ipilimumb lone vs gp100 lone, 0.66; P =.003). 5 Furthermore, there were 20.3% (45.6 vs 25.3) nd 9.8% (23.5 vs 13.7) more ptients live in the ipilimumb-only rm thn in the gp100 rm t 1 yer nd 2 yers, respectively. In the second tril, ptients with tretment-nïve disese who received concurrent regimen of ipilimumb 10 mg/kg nd dcrbzine hd improved OS over single-gent dcrbzine (medin, 11.2 vs 9.1 months; HR, 0.72; P <.001). 6 Higher survivl rtes were lso seen in this tril in the ptients treted with ipilimumb-dcrbzine compred with dcrbzine lone: 47.3% vs 36.3% t 1 yer, 28.5% vs 17.9% t 2 yers, nd 20.8% vs 12.2% t 3 yers. In both trils, ipilimumb ws well tolerted nd ssocited with mngeble sfety profle. Adverse events were primrily immune-relted in nture, consistent with the mechnism of ction of ipilimumb. Observtions from these nd other clinicl trils with ipilimumb resulted in product-specifc guidelines for mnging dverse events to mitigte the impct of immune-relted dverse events. 9 When new drugs re pproved, dt from use in clinicl prctice settings my hve considerble utility in confrming observtions obtined within the controlled setting of phse 3 clinicl trils. Te present study (CA ), multisite observtionl chrt review, ws initited to gther such dt, specifclly on frst-line tretment with ipilimumb in ptients with dvnced melnom in rel-world US tretment setting. Key objectives were to evlute survivl outcomes nd sfety in ptients for whom t lest 12 months of follow-up from the strt of ipilimumb therpy ws vilble, which provides study popultion tht is generlly similr to tht treted in the ipilimumb phse 3 trils. Although this report provides results t medin 1 yer of follow-up, the study protocol includes yerly updtes of survivl for this cohort out to 4 yers. Methods Study design Te study ws n observtionl chrt review study cross 34 US sites nd 15 Cytokine Working Group (CWG) nd 19 cdemic/community non-cwg centers, ech heded by medicl oncologist physicin investigtor (PI). Prticipting sites were instructed to sequentilly identify ll ptients who were treted with ipilimumb nd who met study inclusion nd exclusion criteri. Te PIs nd/or their supervised clinicl reserch stf bstrcted nd trnsferred existing (retrospective) ptient dt from medicl records onto prequlifed, stndrdized cse report forms. Dt collection, mngement, nd vlidtion ctivities were conducted by Medicl Dt Anlytics, contrct reserch orgniztion (Prsippny, New Jersey). Te study protocol ws pproved by either the institutionl review bord (IRB) of the individul prticipting institution or centrlized review bord (New Englnd IRB, Newton, Msschusetts). Te need for ptient informed consent ws determined on site-by-site bsis ccording to site IRB requirements. If site required ptient consent, then ll ptients who were still live nd eligible for the study were consented. Ptients Eligible ptients could hve unresectble stge III or metsttic (stge IV, M1, b, or c) melnom of ll primry types, including cutneous, noncutneous, nd unknown/unidentifble. Tey hd to be 18 yers or older, t dvnced dignosis, nd hd to hve initited frst-line commercil ipilimumb monotherpy (3 mg/kg q3w 4) during April 2011-September Of note, ptients with brin metstses t the time of inititing or continuing ipilimumb were eligible. Key exclusion criteri included ny previous systemic tretment for dvnced melnom, current or pending prticiption in clinicl tril or expnded ccess progrm, nd concurrent use of therpy for cncer other thn melnom. Ptients who were decesed or live t the time of dt collection were eligible. Ptients could hve received dditionl locl nd/or systemic nticncer therpies, including surgery, rdiotherpy, or non-ipilimumb systemic therpy, following the strt of ipilimumb tretment, provided these were not initited t the sme time s ipilimumb. Study vribles Te following study vribles were collected nd re reported in this nlysis: 132 THE JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY g April
3 Mrgolin et l g Ptient demogrphics nd disese chrcteristics t dignosis of dvnced melnom nd bseline (ipilimumb initition); g Detils of ipilimumb dosing, including number of doses dministered, doses completed, dose delys, tretment discontinutions, nd resons for delys nd discontinution; g Concomitnt nticncer therpy initited fter the strt of nd dministered during ipilimumb tretment nd nticncer therpy provided subsequent to the lst dose of ipilimumb initil tretment, including retretment with ipilimumb; g Survivl-relted dt, including ll-cuse deth dte nd dte lst known to be live; nd g All dverse events scribed to disese or tretment (ipilimumb or other nticncer drugs). Dt on dverse events included type of event nd whether the event ws drug-relted, serious, or ssocited with tretment discontinution. Adverse events were coded using the Medicl Dictionry for Regultory Activities (MedDRA) version 16.1 nd grded ccording to the Common Terminology Criteri for Adverse Events, version Sttisticl nlysis Demogrphic nd disese chrcteristics t bseline, ipilimumb dosing informtion, nd sfety profle dt were summrized for ll ptients. Ctegoricl dt were described using counts with percentges nd continuous dt by medins with rnges. Te primry endpoint for evlution of efectiveness ws OS in months from the dte of ipilimumb initition. Te event of interest ws ll-cuse deth; ptients who were live t lst follow-up were censored. Medin OS nd survivl rte t 1 yer from the dte of ipilimumb initition were estimted for ll ptients using the Kpln-Meier method. Corresponding 95% CI for medin OS were clculted using the method of Brookmeyer nd Crowley, 11 nd the 95% CI for OS rtes t 1 yer were clculted using the log-log trnsformtion. Overll survivl ws computed in d hoc, explortory nlyses for specifc subgroups, including ptients with n Estern Coopertive Oncology Group Performnce Sttus (ECOG PS) of 0 or 1, without brin metstses t dvnced dignosis, with cutneous primry site t dignosis, nd by BRAF muttion sttus. Sttistics on d hoc results were not performed becuse study ws observtionl. All of the nlyses were conducted using SAS version 9 (SAS Institute Inc, Cry, NC). Results A totl of 273 ptients were included in this study. Dt collection ws completed during December 2012-Jnury Te medin times from initil melnom dignosis to dvnced melnom dignosis nd from dvnced melnom dignosis to frst dose of ipilimumb were 16.6 months (rnge, 0-312) nd 1.2 months (rnge, 0-72), respectively. Te medin ge ws 64 yers (rnge, 26-91) nd 64.8% of ptients were men (Tble 1). At the time of dignosis of dvnced disese, 12.1% of ptients hd unresectble stge III disese, 56.0% hd stge IV M1c disese, nd 12.1% hd brin metstses. Te primry site ws cutneous in 88.3% of ptients. Before receiving ipilimumb, 38.1% nd 42.5% of ptients hd ECOG PS 0 or 1, respectively, nd 36.6% hd serum lctte dehydrogense levels greter thn the institutionl upper limit of norml. BRAF muttion sttus ws known for 231 ptients, of whom 50 (21.6%) hd V600 muttion, nd 181 (78.4%) were BRAF wild-type. In ll, 78% of ptients received ll 4 plnned doses of ipilimumb (Supplementl dt). Te most common resons for discontinuing dosing were disese progression (10.3%), drug toxicity (7.0%), nd ptient request (3.7%). Ipilimumb dosing ws delyed once in 14 ptients (5.1%), with the most frequent resons given being fever (1.1%), hypotension (0.7%), nd pruritus (0.7%). No ptient experienced more thn 1 dose dely. Additionl nticncer therpy during ipilimumb tretment ws dministered to 8.4% of ptients, with rdiotherpy being the most frequent type (6.6%; Supplementl dt). Forty-one percent of ptients lso received supportive cre gents, including prednisone (16.1%), ntiemetics (15.0%), nlgesics (13.9%), ntipruritics (10.6%), nd ntimotility gents (6.6%). Tree ptients (1.1%) received levothyroxine for thyroiditis, nd 1 ptient (<1%) received infiximb in ddition to prednisone for dirrhe/colitis. Subsequent to the lst dose of ipilimumb, 126 ptients (46.2%) received dditionl non-ipilimumb nticncer therpy including surgery (9.9%), rdiotherpy (23.1%), cytotoxic chemotherpy (17.9%), trgeted therpy (7.7%), nd non-ipilimumb immunotherpy (4.4%). Eighteen ptients (6.6%) were retreted with ipilimumb ccording to stndrd guidelines nd prctice for retretment, which generlly require ptients to hve experienced n objective response or stbility lsting t lest 3 months nd to hve hd no serious tretment-relted toxicity. Overll, 28.9% of ptients received non-ipilimumb systemic therpy subsequent to the lst dose of ipilimumb. Twenty-nine percent of ptients chieved durble therpeutic beneft nd did not receive ny further ipilimumb; other ptients did not receive further ipilimumb becuse their performnce sttus worsened (12.8%) or they died (24.2%). At medin follow-up of 12.2 months (interqurtile rnge, ), 142 (52.0%) ptients hd died. Medin OS from the strt of ipilimumb tretment ws 14.5 months (95% CI, ), nd 1-yer survivl ws 59.2% (95% CI, ) (Tble 2, Figure 1). Medin Volume 13/Number 4 April 2015 g THE JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY 133
4 OS vlues derived from the d hoc, explortory OS nlyses for ptient subgroups were 21.5 (95% CI, 16.8-not reched) nd 12.8 months (95% CI, ) for ptients with ECOG PS 0 or 1, respectively; 17.5 months (95% CI, ) for ptients without brin metstses; nd 16.8 months (95% CI, ) for ptients with cutneous primry site of dignosis. One-yer survivl rtes for BRAF-mutted, wild-type, nd untested ptients were 71.0% (95% CI, ), 54.9% (95% CI, ), nd 63.6% (95% CI, ), respectively. Adverse events during ipilimumb tretment were reported in 164 ptients (60.1%; Tble 3); these were considered drug-relted nd serious in 53.8% nd 18.7% of ptients, respectively. Te most frequently observed dverse events were skin-relted (29.3%), with rsh, pruritus, nd dermtitis most commonly reported, nd gstrointestinlrelted (27.5%), the most frequent being dirrhe (Tble 4). Drug-relted dverse events were grde 3/4 in 15.7% of ptients (13.9 nd 1.8, respectively), nd there were no toxic deths. Drug-relted dverse events led to discontinution of tretment in 10.6% of ptients, most often becuse of colitis (2.9%), dirrhe (1.8%), nd/or enterocolitis (1.5%). Of the 48 deths (17.6%) tht occurred during tretment, 45 were owing to progressive melnom, 1 ws from nondrug-relted congestive hert filure/myocrdil infrction, 1 from pulmonry embolism, nd 1 from unknown cuses. Discussion Tis multisite observtionl chrt review study is the lrgest study to dte of ipilimumb dministered s pproved for frst-line systemic therpy in ptients with dvnced melnom. It is expected tht ptients treted outside of the controlled setting of rndomized clinicl tril my exhibit greter heterogeneity in demogrphic nd disese chrcteristics thn those in clinicl tril cohort. As with ny recently pproved gent, it ws therefore importnt to ssess the efectiveness nd sfety of ipilimumb observed in routine clinicl prctice. Tis rel-world study ddresses this need nd lso provides vluble dt on the use of ipilimumb t its pproved dose nd schedule in ptients with tretment-nïve dvnced melnom. Clinicl tril experience with ipilimumb 3 mg/kg monotherpy in tretment-nïve ptients with dvnced melnom is limited to 2 phse 2 trils. In the frst, 32 ptients who were chemotherpy-nïve hd medin OS of 11.4 months nd 1-yer survivl of 45%, 12 nd in the second, 40 ptients hd medin OS of 12.9 months nd 1-yer survivl of 60.9%. 13 In the ipilimumb-contining rms of the 2 pivotl phse 3 trils, the medin OS rnge ws months, nd the 1-yer survivl rte rnge ws 45.6%- 47.3%. 5,6 In the present study, the observed medin OS of 14.5 months nd 1-yer survivl rte of 59.2% suggest tht survivl outcomes with ipilimumb in routine clinicl prc- TABLE 1 Ptient demogrphics nd disese chrcteristics Chrcteristic No. of ptients (%) (N = 273) Mle 177 (64.8) Medin ge: 64 yers, rnge tice re consistent with those shown in the controlled phse 3 clinicl tril setting. Of note, the plnned yerly survivl updtes of this observtionl cohort will provide rel-world dt on whether long-term survivl is lso consistent with the durble long-term survivl (>3-5 yers) now shown for 20%-26% of ptients in extended follow-up cross the ipi- Treted t CWG center 162 (59.3) Rce White Blck Asin Unknown Primry site b Cutneous Noncutneous Oculr Mucosl Stge c Stge III (M0) Stge IV (M1) M1 M1b M1c ECOG PS Unknown 260 (95.2) 9 (3.3) 3 (1.1) 1 (<1) 241 (88.3) 32 (11.7) 12 (4.4) 5 (1.8) 33 (12.1) 240 (87.9) 30 (11.0) 57 (20.9) 153 (56.0) 104 (38.1) 116 (42.5) 16 (5.9) 3 (1.1) 34 (12.5) Brin metstses c 33 (12.1) LDH, n (%) d Elevted Norml Not tested BRAF muttion sttus e Positive Negtive Not tested 100 (36.6) 127 (46.5) 46 (16.8) 50 (18.3) 181 (66.3) 42 (15.4) CWG, Cytokine Working Group; Estern Coopertive Oncology Group Performnce Sttus, ECOG PS; LDH, serum lctte dehydrogense At strt of ipilimumb tretment unless otherwise noted. b At initil dignosis of melnom. c At dignosis of dvnced melnom. d Site-defned s >upper limit of norml. e At ny melnom dignosis. 134 THE JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY g April
5 Mrgolin et l TABLE 2 Effccy of frst-line ipilimumb Effccy objective Primry, ll ptients (N = 273) b Vlue Medin OS, mo (95% CI) 14.5 ( ) 1-yer survivl, % (95% CI) 59.2 ( ) Explortory, for subgroups (d hoc nlyses) b ECOG PS 0 (n = 104), medin OS, mo (95% CI) ECOG PS 1 (n = 116), medin OS, mo (95% CI) Without brin metstses (n = 240), medin OS, mo (95% CI) Cutneous primry site of dignosis (n = 241), medin OS, mo (95% CI) BRAF muttion sttus, 1-yer survivl, % (95% CI) c 21.5 (16.8-nr) 12.8 ( ) 17.5 ( ) 16.8 ( ) Positive (n = 50) 71.0 ( ) Wild-type (n = 181) 54.9 ( ) Not tested (n = 42) 63.6 ( ) Estern Coopertive Oncology Group Performnce Sttus, ECOG PS; LDH, serum lctte dehydrogense; OS, overll survivl; PS, performnce sttus Approved 3 mg/kg monotherpy q3w 4. b Medin follow-up, 12.2 months (interqurtile rnge, months). c Frequency of BRAF muttions not representtive of typicl frst-line ptient popultion, nd my refect physicins preference to only tret specifc BRAF mutted ptients with ipilimumb (eg, ptients with less ggressive disese or longer life expectncy). TABLE 3 Overll sfety with frst-line ipilimumb Adverse events Ptients with worst grde, n (%) b (N = 273) Any grde Grde 3 Grde 4 Totl c 164 (60.1) 45 (16.5) 8 (2.9) Drug-relted 147 (53.8) 38 (13.9) 5 (1.8) Serious 51 (18.7) 33 (12.1) 7 (2.6) Drug-relted 38 (13.9) 26 (9.5) 5 (1.8) Leding to discontinution 31 (11.4) 18 (6.6) 4 (1.5) Drug-relted 29 (10.6) 18 (6.6) 3 (1.1) Approved 3 mg/kg monotherpy q3w 4; restricted to dverse events reported between the frst ipilimumb dose nd erliest of 70 dys fter the lst initil dose or, if ipilimumb ws given gin, the dy before the strt of retretment. b Common Terminology Criteri, Version 3.0; there were no Grde 5 dverse events. c Ptients my hve experienced more thn one dverse event. limumb clinicl trils. 14 As expected, the d hoc, explortory OS nlyses of subgroups in this study showed higher OS for ptients with ECOG PS 0, without brin metstses, nd with cutneous primry site. BRAF muttion sttus did not seem to fect survivl. Tese results must be interpreted with cution, however, becuse this ws n observtionl study with inherent limittions. Indeed, it should be noted tht the frequency of BRAF muttions reported here (21.6%) is lower thn the 40%-60% expected in popultion of ptients with primrily cutneous melnoms. 7 Tis fnding my refect the prctice of preferentilly treting ptients with BRAF-mutted tumors with BRAF inhibitors, prticulrly ptients with unfvorble clinicl chrcteristics. In ddition, during the time period covered in this study, clinicl trils of BRAF inhibitors in frst-line therpy for melnom were ongoing nd probbly cptured some ptients who might otherwise hve been treted frst-line with ipilimumb. It remins uncertin whether ptients with BRAF mutted tumors should receive MAPK inhibitors or ipilimumb s frst-line systemic therpy while prospective studies re ongoing to inform clinicl prctice. 15 Retrospective dt suggest tht response to BRAF inhibitor is similr pre- nd post-ipilimumb, but response to ipilimumb my be improved before BRAF inhibitor compred with fter BRAF inhibitor. 16 On the bsis of tht evidence, the use of ipilimumb before BRAF inhibitor hs been recommended, prticulrly in n initil setting of symptomtic or low-volume disese. In the future, however, potentil strtegy my be to strt with trgeted therpy nd then to switch to immunotherpy t the time of best response (before filure occurs). 16,17 Ptients with melnom in the US re treted in both cdemic nd community centers, but ptients with dvnced melnom in the Europen Union nd mny other regions re treted primrily in centrlized cdemic centers. Although the present study ws limited to centers in the US, they were primrily specilized centers (CWG or CWG-flited). Tus, ptients in this cohort were treted by cdemic clinicins who hd clinicl tril experience with ipilimumb tretment, selection of pproprite ptients, nd mnging immune-relted dverse events, nd who were supported by similrly experienced nd dedicted clinicl nd reserch tems. Tis rgubly mkes the study results generlizble to the verge tretment-nïve ptient with dvnced melnom who might be treted with frst-line ipilimumb therpy in centrlized cdemic centers in the Europen Union nd other regions. In contrst to the primrily cdemic setting of our study, the community setting (McKesson Specilty Helth/US Oncology Network) ws exclusively the source of ptients for nother US multisite, retrospective, observtionl cohort study tht ws conducted with the sme objectives during the sme timefrme. 18 In this second study, medin OS ws 11.5 months (95% CI, ) nd 1-yer survivl ws Volume 13/Number 4 April 2015 g THE JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY 135
6 Medin OS 14.5 months (95% CI: ) Proportion live yer survivl 59.2% (95% CI: ) Months Ptients t risk FIGURE 1 Overll survivl from strt of frst-line ipilimumb. N = 273; medin follow-up, 12.2 months (interqurtile rnge: 6.6, 15.9 months). Circles indicte censored observtions. 46.7% (95% CI, ) for the 157-ptient cohort with tretment-nïve dvnced melnom who received ipilimumb monotherpy. Fewer ptients in this community setting cohort received ll 4 cycles of the frst-line ipilimumb (53.8% vs 77.7% in the present study) nd this popultion lso hd higher proportion of ptients with brin metstses (34.4% vs 12.1% in the present study); both of those diferences could hve contributed to the lower survivl observed in the second study. Despite the diferences, the results of these 2 observtionl studies re independently consistent with those from the ipilimumb clinicl trils, which strongly suggest tht improved survivl cn be chieved with ipilimumb in the rel-world tretment settings of both cdemic nd community prctice. Ipilimumb seemed to be well tolerted in this tretment-nïve cohort, with nerly 80% of ptients ble to receive ll 4 of the prescribed doses of ipilimumb. Tis therpy ws lso ssocited with sfety profle similr to tht observed in clinicl trils of ipilimumb t this dose nd schedule. In those trils, the most frequent dverse events occurred in the skin nd gstrointestinl systems. Grde 3/4 drug-relted dverse events were reported in 15.7% (13.9% nd 1.18%, respectively) of ptients in the present study, nd in 17.4%-22.9% ( nd ) of previously treted ptients receiving ipilimumb 3 mg/ kg in the frst pivotl phse 3 study. 6 Of note is tht there were no dverse event-relted deths or gstrointestinl perfortions reported in this study, which possibly refects creful ptient selection nd vigilnt use of the ipilimumb dverse event mngement guidelines, which cll for rigorous monitoring nd prompt intervention with immunosuppressive therpy. 9 Tis intervention, strting with glucocorticosteroids nd sometimes requiring the ddition of djunctive immunosuppressnts such s infiximb (in ptients whose immune-relted dverse events re not well controlled by steroids or to spre ptients the risks inherent with long-term nd/or high-dose glucocorticosteroid therpy), ws shown to prevent the worsening of immunerelted events nd to tret them efectively in nerly ll cses in the phse 3 trils. 5,6 Te results suggest tht the use of these dverse event-mngement guidelines in relworld setting yields mngeble sfety profle similr to tht observed in the ipilimumb clinicl trils. Tis study is limited by its observtionl nture nd the heterogeneity of ptients vilble for inclusion in the report. On the one hnd, the inclusion here of ptients typiclly excluded from most ipilimumb clinicl studies (eg, those with brin metstses) nd others who would lso be expected to hve poorer prognosis (eg, with oculr or mucosl melnom) could unfvorbly fect the ppr- 136 THE JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY g April
7 Mrgolin et l TABLE 4 Adverse events occurring in more thn 5% of ptients with frst-line ipilimumb Adverse event Ptients with worst grde, n (%) b (N = 273) Grde 1 Grde 2 Grde 3 Grde 4 Unknown Any Grde Any c 42 (15.4) 67 (24.5) 45 (16.5) 8 (2.9) 2 (0.7) 164 (60.1) Skin 49 (17.9) 24(8.8) 5 (1.8) 0 2 (0.7) 80 (29.3) Rsh 27 (9.9) 11 (4.0) 2 (0.7) (14.7) Pruritus 22 (8.1) 12 (4.4) 1 (0.4) 0 1 (0.4) 36 (13.2) Dermtitis 17 (6.2) 7 (2.6) 2 (0.7) 0 1 (0.4) 27 (9.9) Gstrointestinl 25 (9.2) 26 (9.5) 21 (7.7) 2 (0.7) 1 75 (27.5) Dirrhe 20 (7.3) 16 (5.9) 4 (1.5) (14.7) Colitis 2 (0.7) 6 (2.2) 10 (3.7) 1 (0.4) 0 19 (7.0) Nuse 8 (2.9) 5 (1.8) 1 (0.4) (5.1) Ftigue 16 (5.9) 31 (11.4) 8 (2.9) (20.1) Nervous system d 9 (3.3) 10 (3.7) 5 (1.8) 2 (0.7) 1 (0.4) 27 (9.9) Endocrine e 2 (0.7) 8 (2.9) 6 (2.2) 1 (0.4) 0 17 (6.2) Approved 3 mg/kg monotherpy q3w 4; restricted to dverse events reported between the frst ipilimumb dose nd erliest of 70 dys fter the lst initil dose or, if ipilimumb ws given gin, the dy before the strt of retretment. bcommon Terminology Criteri, Version 3.0; there were no Grde 5 dverse events. cptients my hve experienced more thn one dverse event. dmost common dverse event of ny grde ws peripherl neuropthy in 12 (4.4%) ptients. Hedche ws the most common Grde 3 dverse event, occurring in 3 (1.1%) ptients. emost common Grde 3 or 4 dverse events were drenl insuffciency nd hypophysitis in 3 (1.1%) ptients ech. ent ctivity nd toxicity experience with ipilimumb. On the other hnd, the exclusion of ptients receiving previous therpy for dvnced disese could fvorbly bis the dt. Further limittions re imposed by the incomplete nture of some dt, loss to follow-up, nd possible overor under-reporting of selected outcomes, especilly dverse events. For the OS nlysis, the censoring of ptients not known to hve died by the time of the dt lock reduces the relibility of the OS results with incresing time; its impct is expected to decline with longer follow-up in this cohort. Finlly, the OS results re confounded by the unknown contribution of dditionl nticncer therpy provided during nd subsequent to initil ipilimumb therpy, including ipilimumb retretment. In conclusion, this report expnds our knowledge of the clinicl profle of ipilimumb in ptients with dvnced melnom who received the drug s frst-line therpy in rel-world clinicl prctice setting. To our knowledge, it is the lrgest study of frst-line ipilimumb for ptients with dvnced melnom treted outside of clinicl tril to dte, nd it included ptients cross ll primry subtypes of melnom, including noncutneous subtypes nd those with brin metstses, for whom clinicl tril dt re limited. 19,20 Te observed medin OS of 14.5 months nd 1-yer survivl rte of 59.2% provide evidence tht the improved survivl outcomes ssocited with ipilimumb tretment in the pivotl clinicl trils re chievble in rel-world clinicl setting. Although these results re subject to the limittions of dt obtined from observtionl studies, they support the efectiveness nd sfety of ipilimumb used t the indicted 3 mg/kg dose nd schedule s frst-line therpy for ptients with dvnced melnom. Acknowledgments Tis study ws presented in prt t the 2013 Europen Cncer Congress, October 2013, nd the 2013 Society for Melnom Reserch Interntionl Congress, November Te uthors tke full responsibility for the content of this publiction nd confrm tht it refects their viewpoint nd medicl expertise. Dt collection, reserch opertions, nd nlytics support were provided by Schifon L Wong, Mrinne Messin, nd John R Penrod of Bristol-Myers Squibb; by nd Pete Wolthof, Cynthi Mchilig, nd Scott Merrill of Medicl Dt Anlytics. Professionl medicl writing ssistnce ws provided by Jennifer Wietzke nd Wrd A. Pedersen t StemScientifc, n Ashfeld Compny, funded by Bristol-Myers Squibb. References 1. Americn Cncer Society, Cncer Fcts & Figures Accessed Mrch 19, Forse AM, Del Mrmol V, de Vries E, Biley EE, Geller AC Biley. Melnom incidence nd mortlity in Europe: new estimtes, persistent disprities. Br J Dermtol. 2012;167: Korn EL, Liu PY, Lee SJ, et l. Met-nlysis of phse II coopertive group trils in metsttic stge IV melnom to determine progression-free nd overll survivl benchmrks for future phse II trils. J Clin Oncol. 2008;26: Grbe C, Eigentler TK, Keilholz U, Huschild A, Kirkwood JM. Systemtic review of medicl tretment in melnom: current sttus nd future prospects. Oncologist. 2011;16: Hodi FS, O Dy SJ, McDermott DF, et l. Improved survivl with ipilimumb in ptients with metsttic melnom. N Engl J Med. 2010;363: Robert C, Toms L, Bondrenko I, et l. Ipilimumb plus dcrbzine for previously untreted metsttic melnom. N Engl J Med. 2011;364: Chpmn PB, Huschild A, Robert C, et l. Improved survivl Volume 13/Number 4 April 2015 g THE JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY 137
8 with vemurfenib in melnom with BRAF V600E muttion. N Engl J Med. 2011;364: Luke JJ, Hodi FS. Ipilimumb, vemurfenib, dbrfenib, nd trmetinib: synergistic competitors in the clinicl mngement of BRAF mutnt mlignnt melnom. Oncologist. 2013;18: Weber JS, Khler KC, Huschild A. Mngement of immune-relted dverse events nd kinetics of response with ipilimumb. J Clin Oncol. 2012;30: Cncer Terpy Evlution Progrm. Common Terminology Criteri for Adverse Events (CTCAE). Version 3.0, DCTD, NCI, NIH, DHHS. August 9, Accessed Mrch 1, Brookmeyer R, Crowley J. A confdence intervl for the medin survivl time. Biometrics. 1982;38: Hersh EM, O Dy SJ, Powderly J, et l. A phse II multicenter study of ipilimumb with or without dcrbzine in chemotherpy-nïve ptients with dvnced melnom. Invest New Drugs. 2011;29: Hmid O, Schmidt H, Nissn A, et l. A prospective phse II tril exploring the ssocition between tumor microenvironment biomrkers nd clinicl ctivity of ipilimumb in dvnced melnom. J Trns Med. 2011;9: Schdendorf D, Hodi FS, Roberts C, et l. Pooled nlysis of longterm survivl dt from phse II nd phse III trils of ipilimumb in unresectble or metsttic melnom. J Clin Oncol. 2014: submitted Mrch Jng S, Atkins MB. Which drug, nd when, for ptients with BRAFmutnt melnom? Lncet Oncol. 2013;14:e60-e Ackermn A, Klein O, McDermott DF, et l. Outcomes of ptients with metsttic melnom treted with immunotherpy prior to or fter BRAF inhibitors. Cncer. 2014; 120: Ascierto PA, Mrgolin K. Ipilimumb before BRAF inhibitor tretment my be more benefcil thn vice vers for the mjority of ptients with dvnced melnom. Cncer. 2014;120: Ptt D, Rembert D, Bhor M, Bhowmik D, Ro S. A rel-world observtionl study of ptients with dvnced melnom receiving frst-line Ipilimumb in community prctice setting. J Cncer Ter. 2014: submitted Mrch Mrgolin K, Ernstof MS, Hmid O, et l. Ipilimumb in ptients with melnom nd brin metstses: n open-lbel, phse 2 tril. Lncet Oncol. 2012;13: Di Gicomo AM, Ascierto PA, Pill L, et l. Ipilimumb nd fotemustine in ptients with dvnced melnom (NIBIT M1): n openlbel, single-rm phse 2 tril. Lncet Oncol. 2012;13: THE JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY g April
Efficacy of Pembrolizumab in Patients With Advanced Melanoma With Stable Brain Metastases at Baseline: A Pooled Retrospective Analysis
Efficcy of Pembrolizumb in Ptients With Advnced Melnom With Stble Brin Metstses t Bseline: A Pooled Retrospective Anlysis Abstrct 1248PD Hmid O, Ribs A, Dud A, Butler MO, Crlino MS, Hwu WJ, Long GV, Ancell
More informationCheckMate 153: Randomized Results of Continuous vs 1-Year Fixed-Duration Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer
CheckMte 53: Rndomized Results of Continuous vs -Yer Fixed-Durtion Nivolumb in Ptients With Advnced Non-Smll Cell Lung Cncer Abstrct 297O Spigel DR, McCleod M, Hussein MA, Wterhouse DM, Einhorn L, Horn
More informationSYNOPSIS Final Abbreviated Clinical Study Report for Study CA ABBREVIATED REPORT
Finl Arevited Clinicl Study Report Nme of Sponsor/Compny: Bristol-Myers Squi Ipilimum Individul Study Tle Referring to the Dossier (For Ntionl Authority Use Only) Nme of Finished Product: Yervoy Nme of
More informationEfficacy of Sonidegib in Patients With Metastatic BCC (mbcc)
AAD 216 eposter 3368 Efficcy of Sonidegib in Ptients With Metsttic BCC (mbcc) Colin Morton, 1 Michel Migden, 2 Tingting Yi, 3 Mnish Mone, 3 Dlil Sellmi, 3 Reinhrd Dummer 4 1 Stirling Community Hospitl,
More informationSupplementary Online Content
Supplementry Online Content Zulmn DM, Pl Chee C, Ezeji-Okoye SC, et l. Effect of n intensive outptient progrm to ugment primry cre for high-need Veterns Affirs ptients: rndomized clinicl tril. JAMA Intern
More informationIntroduction. These patients benefit less from conventional chemotherapy than patients identified as MMR proficient or microsatellite stable 3-5
Nivolumb + Ipilimumb Combintion in Ptients With DNA Mismtch Repir-Deficient/Microstellite Instbility-High Metsttic Colorectl Cncer: First Report of the Full Cohort From CheckMte-142 Abstrct 553 André T,
More informationPNEUMOVAX 23 is recommended by the CDC for all your appropriate adult patients at increased risk for pneumococcal disease 1,2 :
PNEUMOVAX 23 is recommended y the CDC for ll your pproprite dult ptients t incresed risk for pneumococcl disese 1,2 : Adults ged
More informationUniversity of Texas Health Science Center, San Antonio, San Antonio, Texas, USA
Lung Cncer Chemotherpy Given Ner the End of Life by Community Oncologists for Advnced Non-Smll Cell Lung Cncer Jose R. Murillo, Jr., Jim Koeller b,c Methodist Hospitl, Houston, Texs, USA; b University
More informationClinical Study Report Synopsis Drug Substance Naloxegol Study Code D3820C00018 Edition Number 1 Date 01 February 2013 EudraCT Number
EudrCT Number 2012-001531-31 A Phse I, Rndomised, Open-lbel, 3-wy Cross-over Study in Helthy Volunteers to Demonstrte the Bioequivlence of the Nloxegol 25 mg Commercil nd Phse III Formultions nd to Assess
More informationA review of the patterns of docetaxel use for hormone-resistant prostate cancer at the Princess Margaret Hospital
MEDICAL ONCOLOGY A review of the ptterns of docetxel use for hormone-resistnt prostte cncer t the Princess Mrgret Hospitl S.N. Chin MD,* L. Wng MSc, M. Moore MD,* nd S.S. Sridhr MD MSc* ABSTRACT Bckground
More informationIMpower133: Primary PFS, OS, and safety in a Ph1/3 study of 1L atezolizumab + carboplatin + etoposide in extensive-stage SCLC
IMpower133: Primry PFS, OS, nd sfety in Ph1/3 study of 1L tezolizumb + crbopltin + etoposide in extensive-stge SCLC S. V. Liu, 1 A. S. Mnsfield, 2 A. Szczesn, 3 L. Hvel, 4 M. Krzkowski, 5 M. J. Hochmir,
More informationThe RUTHERFORD-2 trial in heterozygous FH: Results and implications
The RUTHERFORD-2 tril in heterozygous FH: Results nd implictions Slide deck kindly supplied s n eductionl resource by Professor Derick Rl MD PhD Crbohydrte & Lipid Metbolism Reserch Unit University of
More informationImmune-Mediated Adverse Reactions Management Guide
Immune-Medited Adverse Rections Mngement Guide INDICATIONS AND USAGE YERVOY (ipilimumb) is indicted for: Tretment of unresectble or metsttic melnom in dults nd peditric ptients (12 yers nd older) Adjuvnt
More informationCommunity. Profile Lewis & Clark County. Public Health and Safety Division
Community Helth Profile 2015 Lewis & Clrk County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl
More informationCommunity. Profile Big Horn County. Public Health and Safety Division
Community Helth Profile 2015 Big Horn County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl
More informationCommunity. Profile Powell County. Public Health and Safety Division
Community Helth Profile 2015 Powell County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl Risk
More informationCommunity. Profile Yellowstone County. Public Health and Safety Division
Community Helth Profile 2015 Yellowstone County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl
More informationCommunity. Profile Missoula County. Public Health and Safety Division
Community Helth Profile 2015 Missoul County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl Risk
More informationCommunity. Profile Anaconda- Deer Lodge County. Public Health and Safety Division
Community Helth Profile 2015 Ancond- Deer Lodge County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12
More informationCommunity. Profile Carter County. Public Health and Safety Division
Community Helth Profile 2015 Crter County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl Risk
More informationPresented at the 75 th Annual Meeting of the American Academy of Dermatology, Orlando, FL, March 3-7, 2017 METHODS INTRODUCTION OBJECTIVE
Seven-Yer Interim Results from the ESPRIT 10-Yer Postmrketing Surveillnce Registry of Adlimumb for Moderte to Severe Psorisis Frncisco Kerdel, 1 Aln Menter, 2 Jshin J. Wu, 3 Mreike Bereswill, 4 Dilek Arikn,
More informationSafety and Tolerability of Subcutaneous Sarilumab and Intravenous Tocilizumab in Patients With RA
Sfety nd Tolerbility of Subcutneous Srilumb nd Intrvenous Tocilizumb in Ptients With RA Pul Emery, 1 Jun Rondon, 2 Anju Grg, 3 Hubert vn Hoogstrten, 3 Neil M.H. Grhm, 4 Ming Liu, 4 Nncy Liu, 3 Jnie Prrino,
More informationInvasive Pneumococcal Disease Quarterly Report. July September 2017
Invsive Pneumococcl Disese Qurterly Report July September 2017 Prepred s prt of Ministry of Helth contrct for scientific services by Rebekh Roos Helen Heffernn October 2017 Acknowledgements This report
More informationImpact of Pharmacist Intervention on Diabetes Patients in an Ambulatory Setting
Impct of Phrmcist Intervention on Dibetes Ptients in n Ambultory Setting Julie Stding, PhrmD, CDE, Jmie Herrmnn, PhrmD, Ryn Wlters, MS, Chris Destche, PhrmD, nd Aln Chock, PhrmD Dibetes is the seventh-leding
More informationImpact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors
Originl Article Impct of Positive Nodl Metstses in Ptients with Thymic Crcinom nd Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, nd Jennifer L. Sullivn, MD Introduction: Thymic crcinoms
More informationPrognostic significance of pretreatment serum levels of albumin, LDH and total bilirubin in patients with nonmetastatic
Crcinogenesis, 2015, Vol. 36, No. 2, 243 248 doi:10.1093/crcin/bgu247 Advnce Access publiction December 18, 2014 Originl Mnuscript originl mnuscript Prognostic significnce of pretretment serum levels of
More informationOpioid Use and Survival at the End of Life: A Survey of a Hospice Population
532 Journl of Pin nd Symptom Mngement Vol. 32 No. 6 December 2006 NHPCO Originl Article Opioid Use nd Survivl t the End of Life: A Survey of Hospice Popultion Russell K. Portenoy, MD, Un Sibircev, BA,
More informationSafety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients With Relapsing and Primary Progressive Multiple Sclerosis
Sfety of Ocrelizumb in Multiple Sclerosis: Updted Anlysis in Ptients With Relpsing nd Primry Progressive Multiple Sclerosis SL Huser, L Kppos, X Montlbn, H Koendgen, C Chognot, C Li, C Mrcillt, A Prdhn,
More informationCheckMate-142 Study Design
Nivolumb + Ipilimumb Combintion in Ptients With DNA Mismtch Repir-Deficient/Microstellite Instbility-High Metsttic Colorectl Cncer: First Report of the Full Cohort From CheckMte-142 Thierry André, 1 Sr
More informationStart ORKAMBI today. INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION. Sydney Age 4
F O R H E A L T H C A R E P R O F E S S I O N A L S For ptients ge 2 yers nd older who re homozygous for the F508del muttion 1,2 Modify the course. Strt tody. Sydney Age 4 F508del/F508del INDICATIONS AND
More informationkey words: bortezomib, multiple myeloma, retrospective analysis, treatment outcomes, subcutaneous, intravenous
reserch report Effect of Route of Bortezomib Administrtion on Tretment Outcomes in Previously Untreted Ptients with Multiple Myelom: A Retrospective Anlysis from US Community Oncology Prctices Robert M
More informationSponsor / Company: Sanofi Drug substance(s): AVE0005 (aflibercept)
These results re supplied for informtionl purposes only. Prescribing decisions should be mde bsed on the pproved pckge insert in the country of prescription. Sponsor / Compny: Snofi Drug substnce(s): AVE0005
More informationReference Slide Deck. Abstract 553 Abstract 554 Abstract 560
Clinicl Spotlight Immunotherpy Advnces for Colorectl Crcinom in 2018: Newly Relesed Dt From the Gstrointestinl Cncers Symposium in Sn Frncisco Reference Slide Deck Abstrct 553 Abstrct 554 Abstrct 560 Mismtch
More informationPatient Survival After Surgical Treatment of Rectal Cancer
Originl Article Ptient Survivl After Surgicl Tretment of Rectl Cncer Impct of Surgeon nd Hospitl Chrcteristics Dvid A. Etzioni, MD, MSHS 1,2 ; Toni M. Young-Fdok, MD, MS 1 ; Robert R. Cim, MD, MA 2,3 ;
More informationLung cancer is the leading cause of cancer death worldwide, EGFR Mutation and Brain Metastasis in Pulmonary Adenocarcinomas
Originl Article EGFR Muttion nd Brin Metstsis in Pulmonry Adenocrcinoms Dong-Yeop Shin, MD,* Im Il N, MD,* Cheol Hyeon Kim, MD, PhD, Sunhoo Prk, MD, PhD, HeeJong Bek, MD, PhD, nd Sung Hyun Yng, MD, PhD*
More informationSee 17 for PATIENT COUNSELING INFORMATION and Medication Guide. Revised: 10/2017
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use sfely nd effectively. See full prescribing informtion for. (ipilimumb) injection, for intrvenous use
More informationEmerging Options for Thromboprophylaxis After Orthopedic Surgery: A Review of Clinical Data
Emerging Options for Thromboprophylxis After Orthopedic Surgery: A Review of Clinicl Dt Bob L. Lobo, Phrm.D. In four rndomized, controlled studies of ptients undergoing orthopedic surgery, the ntithrombotic
More informationMetformin and breast cancer stage at diagnosis: a population-based study
ORIGINAL ARTICLE METFORMIN AND BREAST CANCER STAGE AT DIAGNOSIS, Leg et l. Metformin nd brest cncer stge t dignosis: popultion-bsed study I.C. Leg md msc,* K. Fung msc,* P.C. Austin phd, nd L.L. Lipscombe
More informationAbstract. Background. Aim. Patients and Methods. Patients. Study Design
Impct of the Use of Drugs nd Substitution Tretments on the Antivirl Tretment of Chronic Heptitis C: Anlysis of Complince, Virologicl Response nd Qulity of Life (CHEOBS). Melin, 1 J.-. Lng, D. Ouzn, 3 M.
More informationAge related differences in prognosis and prognostic factors among patients with epithelial ovarian cancer
MOLECULAR AND CLINICAL ONCOLOGY 9: 329-334, 2018 Age relted differences in prognosis nd prognostic fctors mong ptients with epithelil ovrin cncer KENJI YOSHIKAWA, TAKESHI FUKUDA, RYO UEMURA, HIROAKI MATSUBARA,
More informationYERVOY (ipilimumab) injection, for intravenous use Initial U.S. Approval: 2011
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use sfely nd effectively. See full prescribing informtion for. (ipilimumb) injection, for intrvenous use
More informationThe potential future of targeted radionuclide therapy: implications for occupational exposure? P. Covens
The potentil future of trgeted rdionuclide therpy: implictions for occuptionl exposure? Introduction: Trgeted Rdionuclide Therpy (TRT) Systemic tretment Molecule lbelled with rdionuclide delivers toxic
More informationClinicalTrials.gov Identifier: NCT
Efficcy of Drtumumb, Lenlidomide, nd Dexmethsone Versus Lenlidomide nd Dexmethsone in Relpsed or Refrctory Multiple Myelom Ptients With to 3 Prior Lines of Therpy: Updted Anlysis of POLLUX Sd Z. Usmni,
More informationEVALUATION OF DIFFERENT COPPER SOURCES AS A GROWTH PROMOTER IN SWINE FINISHING DIETS 1
Swine Dy 2001 Contents EVALUATION OF DIFFERENT COPPER SOURCES AS A GROWTH PROMOTER IN SWINE FINISHING DIETS 1 C. W. Hstd, S. S. Dritz 2, J. L. Nelssen, M. D. Tokch, nd R. D. Goodbnd Summry Two trils were
More informationOriginal Article. Breast Care 2016;11: DOI: /
Originl Article Brest Cre 2016;11:323 327 DOI: 10.1159/000452079 Published online: October 24, 2016 Neodjuvnt Chemotherpy with Docetxel, Crbopltin nd Weekly Trstuzumb Is Active in HER2-Positive Erly Brest
More informationClinical Evidence for Second- and Third-Line Treatment Options in Advanced Non-Small Cell Lung Cancer
Clinicl Evidence for Second- nd Third-Line Tretment Options in Advnced Non-Smll Cell Lung Cncer Filippo de Mrinis, Frncesco Grossi b Thorcic Oncology Unit I, Deprtment of Lung Diseses, Sn Cmillo nd Forlnini
More informationY. Yazici 1, D. Moniz Reed 2, C. Klem 2, L. Rosenblatt 2, G. Wu 2, J.M. Kremer 3
Greter remission rtes in ptients with erly versus long-stnding disese in biologic-nive rheumtoid rthritis ptients treted with btcept: post hoc nlysis of rndomised clinicl tril dt Y. Yzici 1, D. Moniz Reed
More informationXII. HIV/AIDS. Knowledge about HIV Transmission and Misconceptions about HIV
XII. HIV/AIDS Knowledge bout HIV Trnsmission nd Misconceptions bout HIV One of the most importnt prerequisites for reducing the rte of HIV infection is ccurte knowledge of how HIV is trnsmitted nd strtegies
More informationEFFECTS OF INGREDIENT AND WHOLE DIET IRRADIATION ON NURSERY PIG PERFORMANCE
Swine Dy 21 EFFECTS OF INGREDIENT AND WHOLE DIET IRRADIATION ON NURSERY PIG PERFORMANCE J. M. DeRouchey, M. D. Tokch, J. L. Nelssen, R. D. Goodbnd, S. S. Dritz 1, J. C. Woodworth, M. J. Webster, B. W.
More informationInput from external experts and manufacturer on the 2 nd draft project plan Stool DNA testing for early detection of colorectal cancer
Input externl experts nd mnufcturer on the 2 nd drft project pln Stool DNA testing for erly detection of colorectl cncer (Project ID:OTJA10) All s nd uthor s replies on the 2nd drft project pln Stool DNA
More informationOlanzapine for the prophylaxis and rescue of chemotherapyinduced nausea and vomiting (CINV): a retrospective study
Originl Article Olnzpine for the prophylxis nd rescue of chemotherpyinduced nuse nd vomiting (CINV): retrospective study Leonrd Chiu, Nichols Chiu, Ronld Chow, Liying Zhng, Mrk Psetk, Jordn Stinson, Brenne
More informationIncreased Relative Mortality in Women With Severe Oxygen-Dependent COPD
CHEST Originl Reserch Incresed Reltive Mortlity in Women With Severe Oxygen-Dependent COPD Mgnus Ekström, MD ; Krl A. Frnklin, MD, PhD ; nd Kerstin E. Ström, MD, PhD COPD Bckground: Although the incidence
More informationTarget: 10 mg/day within several days Schizophrenia in adolescents (2.1)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ZYPREXA sfely nd effectively. See full prescribing informtion for ZYPREXA. ZYPREXA (olnzpine) Tblet
More informationFor Adults With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)
For Adults With Previously Treted Advnced Non-Smll Cell Lung Cncer (NSCLC) individuls depicted re models used for illustrtive purposes only. It cn be overwhelming to lern tht your previously treted dvnced
More informationMay 28, Congressional Requesters
United Sttes Government Accountbility Office Wshington, DC 20548 My 28, 2010 Congressionl Requesters Subject: Federl Funds: Fiscl Yers 2002-2009 Obligtions, Disbursements, nd Expenditures for Selected
More informationThe Centers for Disease
originlcontributions Evluting the HIV Continuum of Cre within Lrge Integrted Helth System by Michel J. Willims, PhrmD nd Thoms J. Dilworth, PhrmD Abstrct Objective: The primry study objective ws to describe
More informationSupplementary Online Content
Supplementry Online Content Rieckmnn N, Kronish IM, Shpiro PA, Whng W, Dvidson KW. Serotonin reuptke inhibitor use, depression, nd long-term outcomes fter n cute coronry : prospective cohort study. JAMA
More informationManagement of Relapsed/Refractory Follicular Lymphoma
April 2018 Volume 16, Issue 4, Supplement 10 Mngement of Relpsed/Refrctory Folliculr Lymphom n How I Tret Relpsed/Refrctory Folliculr Lymphom: An Expert Perspective n Highlights from: The 2017 Americn
More informationInvasive Pneumococcal Disease Quarterly Report July September 2018
Invsive Pneumococcl Disese Qurterly Report July Septemer Introduction Since 17 Octoer 2008, invsive pneumococcl disese (IPD) hs een notifile to the locl Medicl Officer of Helth under the Helth Act 1956.
More informationTR Spitzer 1, CJ Friedman 2, W Bushnell 2, SR Frankel 3, J Raschko 4. Summary:
(2000) 26, 203 210 2000 Mcmilln Publishers Ltd All rights reserved 0268 3369/00 $15.00 www.nture.com/bmt Double-blind, rndomized, prllel-group study on the efficcy nd sfety of orl grnisetron nd orl ondnsetron
More informationEffectiveness of Belt Positioning Booster Seats: An Updated Assessment
ARTICLES Effectiveness of Belt Positioning Booster Sets: An Updted Assessment AUTHORS: Kristy B. Arbogst, PhD, Jessic S. Jermkin, DSc, Michel J. Klln, MS, b nd Dennis R. Durbin, MD, MSCE,b Center for Injury
More informationMetabolic Syndrome and Health-related Quality of Life in Obese Individuals Seeking Weight Reduction
Metbolic Syndrome nd Helth-relted Qulity of Life in Obese Individuls Seeking Weight Reduction Adm Gilden Tsi 1, Thoms A. Wdden 1, Dvid B. Srwer 1, Robert I. Berkowitz 1, Leslie G. Womble 1, Louise A. Hesson
More informationSeasonal influenza vaccination programme country profile: Ireland
Sesonl influenz vccintion progrmme country profile: Irelnd 2012 13 Seson Bckground informtion Influenz immunistion policy nd generl fcts bout Irelnd Volume indices of GDP per cpit in 2011 nd 2013 (EU-
More informationDiabetes affects 29 million Americans, imposing a substantial
CLINICAL Comprtive Effectiveness nd Costs of Insulin Pump Therpy for Dibetes Ronld T. Ackermnn, MD, MPH; Amish Wlli, MD, MS; Rymond Kng, MA; Andrew Cooper, MPH; Theodore A. Prospect, FSA, MAAA; Lewis G.
More informationTrends in antihypertensive and lipidlowering therapy in subjects with type II diabetes: clinical effectiveness or clinical discretion?
ORIGINAL ARTICLE Trends in ntihypertensive nd lipidlowering therpy in subjects with type II dibetes: clinicl effectiveness or clinicl discretion? MC Gulliford, J Chrlton nd R Ltinovic Deprtment of Public
More informationOne of the most important biological mechanisms of
Brief Report Serum Thymidine Kinse 1 Activity in the Prognosis nd Monitoring of Chemotherpy in Lung Cncer Ptients: A Brief Report Benjmin Nismn, PhD,* Hovv Nechushtn, MD, PhD,* Him Birn, MD, Hds Gntz-Sorotsky,
More informationFor Adults with Metastatic Melanoma
For Adults with Metsttic Melnom The + YERVOY Regimen ws shown to reduce the risk of disese progression by nerly 60% compred to YERVOY lone. Hlf of the ptients on + YERVOY were live t 11.5 months without
More informationRecall Bias in Childhood Atopic Diseases Among Adults in The Odense Adolescence Cohort Study
Syddnsk Universitet Recll Bis in Childhood Atopic Diseses Among Adults in The Odense Adolescence Cohort Study Mørtz, Chrlotte G; Andersen, Klus Ejner; Bindslev-Jensen, Crsten Published in: Act Dermto-Venereologic
More informationFirst-line and Maintenance Treatment with ALIMTA therapy for advanced nonsquamous non-small cell lung cancer (NSCLC)
YOUR LIFE. First-line nd Mintennce Tretment with ALIMTA therpy for dvnced nonsqumous non-smll cell lung cncer (NSCLC) ALIMTA is pproved by the FDA in combintion with cispltin (nother chemotherpy drug)
More informationRisks for All-Cause Mortality: Stratified by Age, Estimated Glomerular Filtration Rate and Albuminuria
Clinicl Prctice: Mini-Review Received: My 20, 2016 Accepted fter revision: December 14, 2016 Published online: Jnury 27, 2017 Risks for All-Cuse Mortlity: Strtified by Age, Estimted Glomerulr Filtrtion
More informationResults. Table 1: Demographic and Baseline Characteristics, Open-Label Safety Population Prior Double-Blind OC/APAP ER (n=77)
Open-Lbel Extension of Rndomized, Double-Blind, Plcebo-Controlled, Phse 3 Study of the Sfety nd Anlgesic Efficcy of MNK-795 Oxycodone/Acetminophen Extended-Relese (OC/APAP ER) Tblets in n Acute Pin Model
More informationA Two-Stage Sampling Method for Clinical Surveillance of Individuals in Care for HIV Infection in the United States
Reserch Articles A Two-Stge Smpling Method for Clinicl Surveillnce of Individuls in Cre for HIV Infection in the United Sttes Ptrick S. Sullivn, DVM, PhD John M. Kron, PhD Fye E. Mlitz, MPH b Stephnie
More informationGemmis Injection 38 mg/ml
Gemmis Injection 8 mg/ml Gemcitbine (Gemcitbine HCl) is nucleoside nlogue tht exhibits nti-tumor ctivity. The empiricl formul for Gemcitbine HCl is C 9H 11F 2N O.HCl. It hs moleculr weight of 299.66. Gemcitbine
More informationEsophageal carcinoma is the eighth most common cancer
ORIGINAL ARTICLE Tumor-Strom Rtio Is n Independent Predictor for Survivl in Esophgel Squmous Cell Crcinom Ki Wng, MD,* Wei M, MD,* Jinbo Wng, MD,* Ling Yu, MD, Xiomei Zhng, MD, Zhenbo Wng, MD, Bingxu Tn,
More informationAssessment of Depression in Multiple Sclerosis. Validity of Including Somatic Items on the Beck Depression Inventory II
Assessment of Depression in Multiple Sclerosis Vlidity of Including Somtic Items on the Beck Depression Inventory II Peggy Crwford, PhD; Noh J. Webster, MA Signs nd symptoms of multiple sclerosis (MS)
More informationBENIGN ulceration along the greater curvature of the pars media of the
BENIGN ULCERS OF THE GREATER CURVATURE OF THE STOMACH Report of Two Cses CHARLES H. BROWN, M.D. Deprtment of Gstroenterology nd ANTHONY D. INTRIERE, M.D.* BENIGN ulcertion long the greter curvture of the
More informationInhaled Corticosteroid Is Associated With an Increased Risk of TB in Patients With COPD
CHEST Originl Reserch Inhled Corticosteroid Is Associted With n Incresed Risk of TB in Ptients With COPD Jung-Hyun Kim, MD ; Ji-Soo Prk, MD ; Kyung-Ho Kim, MD ; Hye-Cheol Jeong, MD ; Eun-Kyung Kim, MD
More informationDOSAGE FORMS AND STRENGTHS HIGHLIGHTS OF PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ALIMTA sfely nd effectively. See full prescribing informtion for ALIMTA. ALIMTA (pemetrexed disodium)
More informationFertility in Norwegian testicular cancer patients
DOI: 0.054/ bjoc.999.0989, vilble online t http://www.idelibrry.com on Fertility in Norwegin testiculr cncer ptients SD Fosså nd Ø Krvdl 2 The Norwegin Rdium Hospitl, Montebello, N-030 Oslo, Norwy; 2 The
More informationReport of the Conference on Low Blood
1046 Report of the Conference on Low Blood Cholesterol: Mortlity Associtions Dvid Jcobs, PhD; Henry Blckburn, MD; Millicent Higgins, MD; Dwyne Reed, MD, PhD; Hiroysu Iso, MD; Grdner McMilln, MD, PhD; Jmes
More informationCorrelations Between Cytogenetic and Molecular Monitoring Among Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Originl Articles Correltions Between Cytogenetic nd Moleculr Monitoring Among Ptients With Newly Dignosed Chronic Myeloid Leukemi in Chronic Phse Post Hoc Anlyses of the Rtionle nd Insight for Gleevec
More informationUsing Paclobutrazol to Suppress Inflorescence Height of Potted Phalaenopsis Orchids
Using Pcloutrzol to Suppress Inflorescence Height of Potted Phlenopsis Orchids A REPORT SUBMITTED TO FINE AMERICAS Linsey Newton nd Erik Runkle Deprtment of Horticulture Spring 28 Using Pcloutrzol to Suppress
More informationMortality of patients with multiple sclerosis: a cohort study in UK primary care
Mortlity of ptients with multiple sclerosis: cohort study in UK primry cre The Hrvrd community hs mde this rticle openly vilble. Plese shre how this ccess benefits you. Your story mtters Cittion Jick,
More informationkey words: chronic obstructive pulmonary disease, beta agonists, Medicare, health care costs, health care utilization
reserch report Helth Cre Use nd Costs Among Medicre Ptients With Chronic Obstructive Pulmonry Disese Treted With Short-Acting Bet Agonists or Long-Acting Bet Agonists Flvi Ejzykowicz, PhD; 1 Vmsi K Bollu,
More informationAppendix J Environmental Justice Populations
Appendix J Environmentl Justice s [This pge intentionlly left blnk] Tble of Contents REFERENCES...J-2 Pge LIST OF TABLES Pge Tble J-1: Demogrphic Overview of Bruinsburg Site Project Are... J-3 Tble J-2:
More informationReducing the Risk. Logic Model
Reducing the Risk Logic Model ETR (Eduction, Trining nd Reserch) is nonprofit orgniztion committed to providing science-bsed innovtive solutions in helth nd eduction designed to chieve trnsformtive chnge
More informationSee 17 for PATIENT COUNSELING INFORMATION and FDAapproved
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ALIMTA sfely nd effectively. See full prescribing informtion for ALIMTA. ALIMTA (pemetrexed for injection),
More informationIntroduction to Study Designs II
Introdution to Study Designs II Commonly used study designs in publi helth & epidemiologi reserh Benjmin Rihrd H. Muthmbi, DrPH, MPH Stte HIV Epidemiologist HIV Epidemiology Investigtion Setion PA Deprtment
More informationAddendum to the Evidence Review Group Report on Aripiprazole for the treatment of schizophrenia in adolescents (aged years)
Addendum to the Evidence Review Group Report on Aripiprzole for the tretment of schizophreni in dolescents (ged 15-17 yers) Produced by Authors Correspondence to Southmpton Helth Technology Assessments
More informationIn the treatment of cardiovascular disease (CVD), national
n report n Beyond LDL Cholesterol: The Role of Elevted Triglycerides nd Low HDL Cholesterol in Residul CVD Risk Remining After Sttin Therpy Peter Algon Jr, MD, FACC In the tretment of crdiovsculr disese
More informationThe Association of Gender With Quality of Health in Peripheral Arterial Disease Following Peripheral Vascular Intervention
The Assocition of Gender With Qulity of Helth in Peripherl Arteril Disese Following Peripherl Vsculr Intervention Sudrshn Pudel, MD 1 ; Anwr Zitoun, MD 1 ; Sif Al-Njfi, MD 2 ; Ther Mus, MD 3 ; Susn Szpunr,
More informationLung cancer is the most common cause of cancer deaths in
Originl Article A Phse I/II Study of Bortezomib in Combintion with Pclitxel, Crbopltin, nd Concurrent Thorcic Rdition Therpy for Non Smll-Cell Lung Cncer North Centrl Cncer Tretment Group (NCCTG)-N0321
More informationPD L1 expression is associated with advanced non small cell lung cancer
ONCOLOGY LETTERS 12: 921-927, 2016 PD L1 expression is ssocited with dvnced non smll cell lung cncer ZHIQUAN CHEN 1 3, JIANDONG MEI 3 5, LUNXU LIU 4,5, GUOCHEN WANG 2, ZUOSHENG LI 2, JINGPU HOU 2, QIUYANG
More informationProstate cancer is among the most common malignancies
Implictions of Evolving Delivery System Reforms for Prostte Cncer Cre Brent K. Hollenbeck, MD, MS; Mggie J. Bierlein, MS; Smuel R. Kufmn, MS; Lindsey Herrel, MD; Ted A. Skolrus, MD, MPH; Dvid C. Miller,
More informationClinical statistics analysis on the characteristics of pneumoconiosis of Chinese miner population
Originl Article Clinicl sttistics nlysis on the chrcteristics of pneumoconiosis of Chinese miner popultion Mei-Fng Wng 1 *, Run-Ze Li 2 *, Ying Li 2, Xue-Qin Cheng 1, Jun Yng 1, Wen Chen 3, Xing-Xing Fn
More informationWSU Tree Fruit Research and Extension Center, Wenatchee (509) ext. 265;
FINAL REPORT WTFRC Project # AH-1-5 WSU Project # 13C-355-3 Project title: PI: Orgniztion: Coopertors: of Sunburn in Apples with RAYNOX Lrry Schrder, Horticulturist WSU Tree Fruit Reserch nd Extension
More informationAsian Journal of Andrology (2017) 19,
(2017) 19, 20 25 2017 AJA, SIMM & SJTU. All rights reserved 1008-682X www.sindro.com; www.jndrology.com Prostte Cncer Open Access ORIGINAL ARTICLE Refining the Americn Urologicl Assocition nd Americn Society
More informationReview TEACHING FOR GENERALIZATION & MAINTENANCE
Gols By the end of clss, you should be ble to: Explin wht generliztion is, why it is criticl for techers to know how to tech so tht it occurs, nd give n exmple of it from your own experience in the clssroom
More information